Thomasville National Bank boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 42.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 3,937 shares of the company’s stock after purchasing an additional 1,178 shares during the quarter. Thomasville National Bank’s holdings in Eli Lilly and were worth $546,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the business. Perennial Advisors LLC acquired a new position in shares of Eli Lilly and in the 4th quarter worth approximately $31,000. DB Wealth Management Group LLC acquired a new stake in Eli Lilly and during the 4th quarter worth $34,000. Retirement Group LLC acquired a new stake in shares of Eli Lilly and in the 4th quarter valued at about $33,000. Archer Investment Corp increased its position in shares of Eli Lilly and by 83.3% in the fourth quarter. Archer Investment Corp now owns 220 shares of the company’s stock valued at $37,000 after acquiring an additional 100 shares during the last quarter. Finally, Accel Wealth Management acquired a new stake in shares of Eli Lilly and in the fourth quarter valued at about $37,000. 75.59% of the stock is owned by hedge funds and other institutional investors.
LLY stock opened at $182.32 on Thursday. The firm has a 50 day moving average of $195.68 and a 200 day moving average of $171.39. The stock has a market capitalization of $174.84 billion, a PE ratio of 29.79, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a quick ratio of 1.06, a current ratio of 1.36 and a debt-to-equity ratio of 3.27. Eli Lilly and Company has a 52 week low of $129.21 and a 52 week high of $218.00.
A number of equities research analysts have recently issued reports on the company. Truist Securities boosted their price objective on Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, March 22nd. Barclays upped their price target on shares of Eli Lilly and from $190.00 to $232.00 and gave the stock an “overweight” rating in a report on Monday, February 1st. Wolfe Research raised shares of Eli Lilly and from a “peer perform” rating to an “outperform” rating and upped their price target for the company from $147.00 to $183.00 in a research report on Thursday, December 10th. Morgan Stanley increased their price objective on shares of Eli Lilly and from $190.00 to $217.00 and gave the stock an “overweight” rating in a research report on Thursday, February 4th. Finally, Cowen upped their target price on shares of Eli Lilly and from $195.00 to $235.00 and gave the stock an “outperform” rating in a report on Friday, February 12th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $193.88.
In related news, major shareholder Lilly Endowment Inc sold 125,284 shares of the business’s stock in a transaction dated Monday, March 8th. The shares were sold at an average price of $209.69, for a total value of $26,270,801.96. Following the sale, the insider now directly owns 110,422,933 shares in the company, valued at approximately $23,154,584,820.77. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 555,284 shares of company stock worth $106,132,302. 0.09% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More: What are municipal bonds?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.